CD4 and colitis: Even more important, CD4+CD62L+ cells from donors which were exposed to CpG motifs had the capacity to inhibit the development of colitis when cotransferred with colitis-inducing CD4+CD62L+ cells from untreated donors, indicating a regulatory potential of CD4+CD62L+ cells from CpG-ODN treated donors [28].